Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nateglinide: A structurally novel, short-acting, hypoglycemic agent.

P. Norman1, X. Rabasseda

  • 1Medical Information Department, Prous Science, Barcelona, Spain. xrabasseda@prous.com

Drugs of Today (Barcelona, Spain : 1998)
|May 24, 2003
PubMed
Summary

Nateglinide, a potassium channel blocker, effectively controls type 2 diabetes by rapidly stimulating insulin secretion to manage postprandial hyperglycemia. Its "fast on-fast off" action offers improved glycemic control with fewer side effects compared to other agents.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Migraine headache treatment with eletriptan, a second-generation serotonin receptor agonist.

Drugs of today (Barcelona, Spain : 1998)·2003
Same author

Amoxicillin-sulbactam: A clinical and therapeutic review.

Drugs of today (Barcelona, Spain : 1998)·2003
Same author

Oxcarbapezine: anticonvulsant profile and safety.

Drugs of today (Barcelona, Spain : 1998)·2003
Same author

Desloratadine: A preclinical and clinical overview.

Drugs of today (Barcelona, Spain : 1998)·2003

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia.
  • Effective glycemic control, particularly of postprandial glucose excursions, is crucial for preventing T2DM complications.
  • Existing oral hypoglycemic agents have varying efficacy and side effect profiles.

Purpose of the Study:

  • To evaluate the efficacy and safety of nateglinide in improving glycemic control in patients with T2DM.
  • To characterize the unique pharmacokinetic and pharmacodynamic profile of nateglinide.
  • To compare nateglinide's effects with other oral antidiabetic agents.

Main Methods:

  • Nateglinide is a pancreatic, beta-cell-selective, K(ATP) potassium channel blocker.

Related Experiment Videos

  • It exhibits rapid binding and dissociation from the SUR1 receptor, resulting in a "fast on-fast off" effect.
  • Clinical studies assessed its impact on insulin secretion and postprandial hyperglycemia.

    • Main Results:

    • Nateglinide rapidly stimulates insulin secretion, restoring the physiological first phase of insulin release.
    • It effectively reduces postprandial hyperglycemia with a short duration of action, minimizing risk of delayed hypoglycemia.
    • Clinical trials confirm its efficacy, tolerability, and superiority in attenuating postprandial glucose spikes compared to other oral agents.

    Conclusions:

    • Nateglinide offers a distinct therapeutic option for T2DM management due to its rapid onset and short duration of action.
    • Its unique profile improves glycemic control and may reduce the risk of vascular complications.
    • Nateglinide demonstrates a favorable safety profile and enhances patient compliance when taken before meals.